Achira Labs: India’s Microfluidic ‘Lab-on-a-Chip’ Technology Bringing Complex Diagnostics to the Point of Care

Modern medical diagnostics often depend on large central laboratories equipped with automated analysers, trained technicians and extensive supporting infrastructure. Although these laboratories can deliver highly accurate results, sending samples to them can create delays that matter when doctors need information quickly.

Bengaluru-based Achira Labs is developing an Indian alternative built around microfluidics: shrinking several laboratory processes into small disposable cartridges that can operate with compact analysers close to the patient.

Founded in 2009, Achira has developed proprietary microfluidic and hydrogel-based diagnostic technologies aimed at bringing quantitative laboratory-style testing to clinics, smaller laboratories and other point-of-care settings. The company says it operates an ISO 13485-compliant manufacturing facility for microfluidic devices.

Shrinking a Diagnostic Laboratory onto a Cartridge

Microfluidics involves controlling extremely small quantities of liquid through miniature channels and structures.

In a conventional diagnostic laboratory, a blood sample may travel through multiple preparation, reaction and detection stages using separate equipment. A microfluidic cartridge attempts to integrate much of this process within a compact device.

Achira’s current μfluidX platform combines a disposable cartridge with a reusable reader. Once the sample enters the cartridge, the system performs the assay and measures the resulting signals automatically. The company describes the technology as a hydrogel-based multiplexed diagnostic platform capable of producing quantitative results at the point of care.

This approach could allow sophisticated tests to move closer to doctors and patients without reproducing the infrastructure of a full-scale pathology laboratory.

Up to Five Tests from a Small Sample

One of the most important features of Achira’s platform is multiplexing.

Instead of testing one biomarker at a time, μfluidX can analyse up to five targets simultaneously. According to the company, the current cartridge requires only about 50 microlitres of sample, while test results can be generated in approximately 35 minutes.

The cartridge comes pre-loaded with reagents designed to remain stable at room temperature. After adding the sample, the operator inserts the cartridge into the reader and initiates the test. The system performs the analysis without requiring continuous manual intervention.

Compatible sample types include whole blood, serum and nasal swabs, giving the underlying platform the flexibility to support several categories of diagnostic tests.

This combination of low sample volume, automation and multiplexing is central to Achira’s effort to bring laboratory capabilities into smaller healthcare environments.

A Compact Reader Instead of a Large Laboratory Analyser

The μfluidX reader is considerably smaller than the automated systems normally associated with central diagnostic laboratories.

Achira lists the reader at approximately 180 × 150 × 150 mm, with a weight of around 2.5 kg. It uses fluorescence-based signal detection and operates from a 12-volt power input.

The disposable cartridge itself measures roughly 74 × 40 × 15 mm and weighs about 18 grams.

The objective is not to eliminate central laboratories. Instead, the technology attempts to move selected tests closer to where medical decisions take place.

For clinics, smaller hospitals and healthcare centres distant from major laboratories, the ability to obtain several quantitative results during a patient visit could reduce dependence on transporting samples and waiting for reports from another location.

Fertility, Thyroid and Respiratory Testing

Achira is developing several multiplexed panels around the μfluidX platform.

Its fertility panel is designed to measure four hormones — FSH, LH, estradiol and progesterone — from serum or whole blood within approximately 35 minutes. These biomarkers can provide clinicians with information relevant to reproductive health and fertility treatment.

The company’s thyroid panel combines TSH, total T3 and total T4 into a single test. Conventional thyroid evaluation often requires measuring these parameters together, making the application particularly suited to multiplexed diagnostics.

A respiratory panel is designed to distinguish between Influenza A, Influenza B, respiratory syncytial virus and COVID-19 using nasal-swab samples.

Achira currently describes these μfluidX panels as upcoming products, while additional assays remain under development.

Moving Toward Tropical Fever Diagnostics

The same platform could have particular relevance in India because several infectious diseases can produce similar early symptoms.

A patient arriving with fever may potentially have dengue, malaria, chikungunya or another infection. Rapidly distinguishing among them can help guide further clinical decisions and treatment.

In 2026, Achira Labs was selected under the Government of India’s Promotion of Research and Innovation in Pharma-MedTech, or PRIP, scheme for a project in the novel medical-device category. In collaboration with the Tata Institute for Genetics and Society, the company is working on a multiplexed microfluidic platform intended to detect dengue, malaria, chikungunya and typhoid from the same patient sample.

Achira also lists a tropical-fever panel among the products currently in its development pipeline.

If such a system can be validated and deployed at scale, it could demonstrate one of the strongest advantages of multiplexed point-of-care diagnostics: testing for several possible causes of illness during a single diagnostic run.

Technology Supported by Years of Indian Biotechnology Development

Achira’s work in microfluidics did not emerge recently.

The Biotechnology Industry Research Assistance Council, or BIRAC, has supported the company’s development over several years. BIRAC has previously described Achira’s technology as a plastic microfluidic device capable of carrying out rapid, multiplexed immunoassays using small amounts of blood or serum. Earlier generations of the technology included the ACIX reader and microfluidic cartridge, with thyroid and fertility cartridges undergoing validation and scale-up.

Achira received a BIRAC Innovator’s Award in 2013 and later received a national award for indigenous product commercialisation in 2016.

The company is also part of the startup ecosystem supported by Bengaluru’s Centre for Cellular and Molecular Platforms, or C-CAMP, which describes Achira’s core focus as rapid, quantitative and multiplexed point-of-care immunoassays.

This illustrates the long development cycle often required for deep-tech medical devices. Unlike consumer software, diagnostic technologies must progress through laboratory research, assay development, engineering, manufacturing processes, clinical validation and regulatory requirements before they can achieve widespread use.

Beyond Microfluidics

Although microfluidics remains central to Achira’s technology portfolio, the company has developed other diagnostic platforms.

Its QuantALFA system combines lateral-flow tests with a compact electronic reader to obtain quantitative measurements rather than relying solely on the visible positive-or-negative lines associated with conventional rapid tests.

Current QuantALFA tests include Cystatin-C for kidney-function assessment, CRP for inflammation and infection, and high-sensitivity CRP. The reader can scan a test within seconds and communicates with a mobile application used to guide testing and record results.

Achira also develops USelect, a magnetic-bead-based sperm-selection technology intended for assisted reproductive procedures.

Together, these technologies show that the company’s broader objective is not simply to build individual diagnostic kits, but to create portable platforms capable of supporting multiple medical applications.

New Diagnostic Panels for Indian Healthcare Needs

Achira’s development pipeline is increasingly focused on diseases and health conditions that have particular relevance to India and other lower-resource healthcare systems.

The company received a Gates Foundation product-development grant in 2024 to support work on an anaemia panel and HbA1c test, with an emphasis on maternal and child health.

In 2025, it received support through the C-CAMP One Health AMR Challenge, backed by ICARS, to develop a rapid point-of-care diagnostic capable of helping distinguish bacterial infections from viral infections.

Achira also lists micronutrient and anaemia panels among products under development.

Such tests could become particularly useful where access to sophisticated laboratory infrastructure remains limited.

An Indian Platform Rather Than an Imported Diagnostic Machine

India has historically depended heavily on imported technologies across several categories of advanced medical equipment and diagnostic instrumentation.

Achira represents a different model.

Its core intellectual property, microfluidic devices, hydrogel sensing technologies, assay-development capabilities, instrumentation and manufacturing processes are being developed within an Indian biotechnology ecosystem.

The company says it has capabilities covering assay development, device design, prototyping and manufacturing, including an ISO 13485-compliant facility for producing microfluidic devices.

This makes Achira particularly relevant to India’s broader effort to increase domestic capabilities in medical devices and biotechnology.

Indigenisation in healthcare does not simply mean assembling imported equipment locally. Developing the underlying diagnostic chemistry, cartridge architecture, sensors, readers and manufacturing methods can create deeper technological capability.

Making Advanced Diagnostics More Decentralised

The long-term significance of microfluidic diagnostics lies in their ability to decentralise testing.

A large central laboratory will continue to remain essential for complex medical investigations. However, many routine and time-sensitive tests could increasingly migrate toward clinics, emergency departments, smaller hospitals and community healthcare facilities.

That shift requires systems that can operate with very small samples, produce reliable quantitative results quickly and demand relatively little specialised infrastructure.

Achira’s μfluidX platform is designed around precisely those requirements.

A patient sample measured in tens of microlitres enters a disposable cartridge. Several biomarkers can be tested at the same time. A compact reader handles the detection, and the result can become available during the same clinical visit.

That is essentially the promise of the lab-on-a-chip concept: taking analytical processes that once occupied an entire laboratory and compressing them into a cartridge small enough to hold in one hand.

A Make in India Story in Medical Deep Tech

Achira Labs highlights a less visible but strategically important part of India’s deep-tech ecosystem.

India’s healthcare industry does not only need more hospitals, laboratories and diagnostic centres. It also needs indigenous technologies capable of making sophisticated medical testing cheaper, faster and easier to deploy.

Microfluidics offers one route toward that objective.

By combining Indian-developed cartridges, hydrogel sensors, multiplexed assays and compact analysers, Achira is attempting to move advanced diagnostics from large laboratories toward the point of care.

More than fifteen years after its founding, the Bengaluru company is now extending that platform into fertility, thyroid, respiratory, anaemia, antimicrobial-resistance and tropical-disease applications.

These systems progress successfully through validation, regulation and commercial deployment, Achira’s technology could help India do more than manufacture diagnostic equipment domestically.

It could help India design the miniature laboratories themselves.

---